﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Academy of Medical Sciences of I.R. Iran</PublisherName>
      <JournalTitle>Archives of Iranian Medicine</JournalTitle>
      <Issn>1029-2977</Issn>
      <Volume>15</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2012</Year>
        <Month>10</Month>
        <DAY>01</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>Association between Serum Levels of MASP-2 and Neutropenic Febrile Attacks in Children with Leukemia</ArticleTitle>
    <FirstPage>0</FirstPage>
    <LastPage>0</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Shiva</FirstName>
        <LastName>Nazari</LastName>
      </Author>
      <Author>
        <FirstName>Mohsen</FirstName>
        <LastName>Ebrahimi</LastName>
      </Author>
      <Author>
        <FirstName>Fatemeh</FirstName>
        <LastName>Abdollah Gorji</LastName>
      </Author>
      <Author>
        <FirstName>Alireza</FirstName>
        <LastName>Abadi</LastName>
      </Author>
      <Author>
        <FirstName>Alireza</FirstName>
        <LastName>Fahimzad</LastName>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">
      </ArticleId>
    </ArticleIdList>
    <History>
    </History>
    <Abstract> BACKGROUND: Infectious complications are a major etiology of morbidity and mortality in febrile neutropenic patients. Low serum mannose-binding lectin (MBL)-associated serine protease-2 (MASP-2) concentration may represent a risk factor for infection in leukemia patients receiving chemotherapy. This study evaluates the relationship between serum levels of MASP-2 with neutropenic febrile attacks in children with leukemia. METHOD: This prospective cohort study conducted between 2009–2010, we measured baseline serum MASP-2 levels by enzyme-linked immunosorbent assay (ELISA) prior to chemotherapy in leukemia patients less than 14 years of age. The relationship of febrile neutropenia (FN) episodes and duration of hospitalization with MASP-2 concentration was analyzed. RESULTS: We evaluated 75 children [38 girls (51%), 37 boys (49%); mean age, 61.6 ± 43.7 months]. There were 8 (10.7%) children with MASP-2 deficiency (&lt; 200 ng/mL). Mean MASP-2 was 673.2 ± 288.7 ng/mL (range: 116–1112). Eight patients had no FN episodes. Of the 129 FN episodes recorded, 19 (average 2.4 times) were from the MASP-2deficient group and 110 (average 1.6 times) were in the normal group. There was a significant difference between the mean MASP-2 concentration and FN episodes (P = 0.043). There was an inverse relationship between FN episodes (r = -0.332, P = 0.004) and the duration of hospitalization (r = -0.334, P = 0.005) with MASP-2 concentration. MASP-2 deficient patients were hospitalized longer than the normal group, which was strongly significant (P &lt; 0.001). CONCLUSION: Our study confirmed the results of several previous studies. MASP-2 deﬁciency in leukemic children treated with chemotherapy was associated with an increased risk of FN episodes, prolonged cumulative duration of hospitalization, and intravenous antimicrobial therapy. </Abstract>
  </Article>
</ArticleSet>